• Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers

    1 month ago - By San Diego Biotechnology

    SAN DIEGO and CALGARY, AB: Multi-center trial is being conducted in collaboration with Roche and AIO Trial is designed to assess the safety and efficacy of pelareorep-atezolizumab combination therapies across multiple gastrointestinal cancer indications Trial builds on prior promising data from pancreatic and colorectal cancer trials SAN DIEGO and CALGARY,...
    Read more ...